Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Central nervous system vascular disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Central nervous system vascular disorders. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-002935-27 Sponsor Protocol Number: 41208 Start Date*: 2012-12-13
    Sponsor Name:Maastricht University Medical Center
    Full Title: Diagnostic value of novel MR imaging techniques for the primary staging and restaging of rectal cancer
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    14.1 10018065 - General disorders and administration site conditions 10018065 General disorders and administration site conditions SOC
    14.1 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002217-34 Sponsor Protocol Number: FITO-01/21 Start Date*: 2022-07-26
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
    Full Title: Tuscany project to investigate on efficacy and safety of Cannabis phytotherapic preparations for the treatment of Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents: a pro...
    Medical condition: Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020319-34 Sponsor Protocol Number: DGD 44-050 Start Date*: 2010-09-30
    Sponsor Name:GUERBET
    Full Title: SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) LESIONS
    Medical condition: Patient with Central Nervous System (CNS) Lesions
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016066-91 Sponsor Protocol Number: EPO200901 Start Date*: 2010-03-10
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL
    Medical condition: ALS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003536-36 Sponsor Protocol Number: ACP-103-046 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerativ...
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-003079-20 Sponsor Protocol Number: 18F-AV-45-C02 Start Date*: 2013-01-10
    Sponsor Name:AVID RADIOPHARMACEUTICALS, INC.
    Full Title: Evaluation of florbetapir (18F) PET in subjects participating in the IRCCSFBF protocol
    Medical condition: Alzheimer's disease and other neurodegenerative diseases, as for example Dementia with Lewy bodies, Parkinson Dementia, Vascular Dementia and Tau Protein associated Dementia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    14.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012086-66 Sponsor Protocol Number: T05018-1001 Start Date*: 2009-12-01
    Sponsor Name:Grifols Inc
    Full Title: A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke
    Medical condition: Thrombus in acute ischemic stroke of the middle cerebral artery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10008190 Cerebrovascular accident PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) SK (Completed) AT (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2019-001476-11 Sponsor Protocol Number: AL002-2 Start Date*: 2020-11-12
    Sponsor Name:Alector Inc.
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
    Medical condition: Early Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003179-32 Sponsor Protocol Number: ToL54304 Start Date*: 2016-02-03
    Sponsor Name:University Medical Center Utrecht
    Full Title: PREvention of Complications to Improve Outcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment.
    Medical condition: Stroke (ischaemic stroke or intracerebral hemorrhage)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    21.1 10029205 - Nervous system disorders 10022754 Intracerebral hemorrhage LLT
    22.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002353-38 Sponsor Protocol Number: OHIRC-20150866 Start Date*: 2017-08-31
    Sponsor Name:Ottawa Heart Institute Research Corporation (OHIRC)
    Full Title: The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
    Medical condition: risk of stroke by atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    22.1 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    20.0 10042613 - Surgical and medical procedures 10059864 Cardiac ablation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000619-26 Sponsor Protocol Number: BAY59-7939/16416 Start Date*: 2014-06-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and...
    Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037439 Pulmonary thrombotic and embolic conditions HLT
    14.1 10047065 - Vascular disorders 10034572 Peripheral embolism and thrombosis HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) NL (Completed) NO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002222-23 Sponsor Protocol Number: P170932J Start Date*: 2019-02-05
    Sponsor Name:APHP
    Full Title: Cobimetinib for BRAF-wild-type histiocytoses : a randomized, placebo-controlled, double blind study
    Medical condition: Histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. patients with BRAF-wild type.
    Disease:
    Population Age: Gender:
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003218-17 Sponsor Protocol Number: TRANEX1 Start Date*: 2012-11-08
    Sponsor Name:Hospital Universitario La Paz
    Full Title: Efficacy of topical tranexamic acid versus intravenous administration to reduce blood transfussion rate in total knee arthroplasty surgery: phase III, unicentric, controlled,double blind, randomiz...
    Medical condition: El sangrado perioperatorio es común en intervenciones quirúrgicas de ortopedia, especialmente en los reemplazos de rodilla con una estimación media de transfusión de concentrados de hematíes de un...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10033380 Pain back LLT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10052438 Paranasal sinus discomfort PT
    15.0 10021428 - Immune system disorders 10040562 Shock anaphylactic anaphylactoid LLT
    15.0 10017947 - Gastrointestinal disorders 10047700 Vomiting PT
    15.0 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    15.0 10047065 - Vascular disorders 10066331 Arterial hypotension LLT
    15.0 10015919 - Eye disorders 10047514 Vision central defective LLT
    15.0 10029205 - Nervous system disorders 10051385 Drug-induced headache LLT
    15.0 10047065 - Vascular disorders 10043566 Thromboembolism LLT
    15.0 10015919 - Eye disorders 10047518 Vision disorders HLGT
    15.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    15.0 10029205 - Nervous system disorders 10027606 Migraine type headaches LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004208-37 Sponsor Protocol Number: 20120153 Start Date*: 2013-04-23
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of AMG-145 Treatment on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patie...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10011079 Coronary artery disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) BE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) DE (Completed) GR (Completed) FI (Prematurely Ended) NO (Completed) IE (Completed) DK (Prematurely Ended) IS (Completed)
    Trial results: View results
    EudraCT Number: 2012-002764-27 Sponsor Protocol Number: NILVAD2012 Start Date*: 2013-02-04
    Sponsor Name:St James's Hospital
    Full Title: A European multicenre double-blind placebo controlled phase III trial of nilvadipine in mild to moderate Alzheimer's disease.
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) GR (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000106-38 Sponsor Protocol Number: JCAR017-BCM-001 Start Date*: 2018-06-14
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCEND WORLD)
    Medical condition: Aggressive B-cell Non Hodgkin Lymphoma (B-NHL)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) FI (Completed) ES (Restarted) DE (Completed) AT (Completed) NL (Ongoing) GB (Temporarily Halted) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003964-30 Sponsor Protocol Number: BIOVAS Start Date*: 2020-10-22
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vascu...
    Medical condition: Non-ANCA associated vasculitides: 1. Giant cell arteritis (GCA) 2. Takayasu’s arteritis (TA) 3. Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN) 4. Relapsing p...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001247-39 Sponsor Protocol Number: CV185-362 Start Date*: 2017-04-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart ...
    Medical condition: Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019273 Heart disease congenital PT
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10019276 Heart disease, unspecified LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    20.0 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FI (Completed) AT (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003248-36 Sponsor Protocol Number: 61383082 Start Date*: 2011-09-30
    Sponsor Name:Central Military Hospital
    Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.
    Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016335 Feeling hot and cold LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037872 Rash NOS LLT
    14.0 10037175 - Psychiatric disorders 10032168 Other insomnia LLT
    14.0 10007541 - Cardiac disorders 10008481 Chest pain - cardiac LLT
    14.0 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    14.0 10029205 - Nervous system disorders 10048324 Dizziness aggravated LLT
    14.0 10029205 - Nervous system disorders 10033777 Paraesthesia distal LLT
    14.0 10022891 - Investigations 10050786 Fasting blood glucose increased LLT
    14.0 10018065 - General disorders and administration site conditions 10022096 Injection site reaction NOS LLT
    14.0 10021881 - Infections and infestations 10034838 Pharyngitis NOS LLT
    14.0 10018065 - General disorders and administration site conditions 10016259 Fatigueability LLT
    14.0 10021428 - Immune system disorders 10020762 Hypersensitivity type I LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048412 Back pain aggravated LLT
    14.0 10021428 - Immune system disorders 10020756 Hypersensitivity reaction LLT
    14.0 10017947 - Gastrointestinal disorders 10028822 Nauseated LLT
    14.0 10047065 - Vascular disorders 10048347 Flushing aggravated LLT
    14.0 10029205 - Nervous system disorders 10024857 Loss of consiousness LLT
    14.0 10029205 - Nervous system disorders 10019218 Headache NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037096 Pruritus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001322-54 Sponsor Protocol Number: CS/2018/6632 Start Date*: 2020-06-15
    Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust
    Full Title: Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial
    Medical condition: Brain injury during open heart valve surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10067967 Brain injury PT
    21.1 100000004865 10048935 Open heart surgery LLT
    20.0 10029205 - Nervous system disorders 10077808 Mild neurocognitive disorder LLT
    20.0 10047065 - Vascular disorders 10001526 Air embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:36:55 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA